Investors are almost always on the lookout for the next stock to track, and this morning, many of them may consider taking a look into the Zivo Bioscience Inc. (OTC:ZIVO) stock. On Tuesday, the company was in the news after making a significant announcement. It should be noted that Zivo is a biotech and agtech research and development firm involved in producing medicinal, nutritional, and therapeutic offerings from proprietary algae cultures.
Yesterday, the company was in the news after it announced positive efficacy results following the completion of the 42-day coccidiosis challenge study. In the news release, Zivo noted that the development was further reinforcement of the efficacy of its unique immune modulation treatment meant for treating coccidiosis in broiler chickens. The company announced in its news release that its product candidate was meant for use in poultry feed and for boosting immune responses. That would help the birds combat coccidiosis effectively and manage the ill effects of the condition without the use of antibiotics.
The design that had been created for the study was on the same lines as the one that had been used in a previous 28-day challenge study. The design had been extended to 42 days so as to match the real-world conditions of the broiler production space. In this context, it ought to be noted that the company also revealed that the ZIVO product’s performance was at a level that matched that of a leading anticoccidial offering.
The Chairman and Chief Executive Officer of Zivo spoke about the development yesterday. He noted that everyone at the company was delighted with the fact that the results validated the previous 28-day study that had been conducted on broiler chickens. It remains to be seen if the Zivo stock gets any traction today.